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INTRODUCTION 
The oral route is considered as the most promising route of 
drug delivery. Conventional drug delivery system achieves 
as well as maintains the drug concentration within the 
therapeutically effective range needed for treatment, only 
when taken several times a day. This results in a 
significant fluctuation in drug levels. The most important 
objectives of these new drug delivery systems are: first, it 
would be single dose, which releases the active ingredient 
over an extended period of time. Second, it should deliver 
the active entity directly to the site of action, thus, 
minimizing or eliminating side effects. To overcome the 
limitations of conventional drug delivery system, floating 
tablets have been developed. Drugs that have narrow 
absorption window in the gastrointestinal tract will have 
poor absorption. For these drugs, gastro retentive drug 
delivery systems offer the advantages in prolonging the 
gastric emptying time.  
MATERIALS AND METHODS 
DiltiazemHCl was gift sample from Devi’s laboratories 
Ltd, India andHydroxypropyl methyl cellulose K4M 
(HPMC K4M) from  Colorcon Asia Pvt.Limited, Goa, 
India and  Hydroxypropyl methyl cellulose K100M 
(HPMC K100M) from Colorcon Asia Pvt. Limited, Goa, 
India and  Carbopol 934S. D. Fine Chemicals Ltd. 
Mumbai, India and  Ethyl cellulose Asha cellulose Pvt. 
Ltd, India and  Xanthan gum from  Otto 
ChemicaBiochemica Reagents, India and Sodium 
bicarbonate, Lactose  and  Hydrochloride Acid obtained 
from  Finar chemicals, Ahmadabad, India  and Micro 
crystalline cellulose (MCC)  obtained from Acme 
pharmaceuticals, Kherva (Gujarat), India and  Talc  and  
Magnesium stearate obtained from  S. D. Fine Chemicals 
Ltd. Mumbai, India. 
Method forpreparation of DiltiazemHCL floating tablets 
All the ingredients weigh accurately the required quantity 
and mix thoroughly to get uniform powder blend passed 
through 60 # sieve. Talc and Magnesium stearate were 
finally added as glidant and lubricant respectively and 
finally compressed with the help ofrimek mini tablet press 
II MT. 
FORMULATION 
Preliminary trials of DiltiazemHCl formulation: In 
present investigation attempt was made to prepare 
sustained (gastro retentive layer) release formulation of 
diltiazemHCl using different grades of HPMC, ethyl 
cellulose, xanthan gum and carbopol as polymers by direct 
compression techniques using rimek mini tablet press 
machine. 
In preliminary study, different batches were prepared as 
per the composition given in Table 1. It was found that the 
batches Dtz3, Dtz4 and Dtz6 show the premature drug 
release in the initial first hour. That may be due to 
disintegration of the tablet before the gel formation occurs 
by the polymer. Batches Dtz1, Dtz2, Dtz5 and Dtz8 shows 
the release retardation up to some extends but that was not 
up to the 24 hrs. Batch Dtz7 shows the good release 
retardation but the drug release in the first hour is higher 
due to the burst release of the drug. This initial burst 
release may be occurs due to the rapid hydration of the 
polymer (HPMC K100M)which is hydrophilic in nature. 
While the dissolution study of batch Dtz9 shows the 
decrease in initial burst release of the drug and sustained 
effect up to 24.0 hrs having 98.88% releases at the end of 
24.0 hrs. The combination of HPMC K100M and 
carbopol-934 forms the gel having the higher viscosity that 
may be responsible for the decrease in initial burst release 
of drug and for the sustained effect up to 24 hrs. Therefore, 
the composition of batch Dtz9 was selected for further 
work.
ABSTRACT 
The investigation was concerned with design and characterization of oral sustained release gastro retentive floating tablets of 
DiltiazemHCl in order to improve efficacy and better patient compliance. Present investigation was to formulate, evaluate and 
optimize gastro retentive tablet of DiltiazemHCl. This tablets released drug till 24 hrs due to floating mechanism of polymers. 
Gastro retentive floating tablets were prepared by direct compression method using various proportions of polymersHPMC 
K4M, HPMC K100M,Carbopol 934, Ethyl cellulose, Xanthan gum along with Sodium bicarbonatethe sustained release 
behaviour of the fabricated tablets was investigated. Tablets were prepared by directcompretiontechnique.Formulation was 
optimized on the basis of acceptable tablet properties and in vitro drug release. The resulting formulation produced robust 
tablets with optimum hardness, consistent weight uniformity and low friability. All tablets but one exhibited gradual and near-
complete sustained release for DiltiazemHCl (90-100%) at the end of 24 h. The results of dissolution studies indicated that 
formulation Dtz15 was found to be most successful as it exhibits drug release pattern very close to theoretical release profile. 
A decrease in release kinetics of the drug was observed on increasing polymer ratio. 
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Table 1: Preliminary trial formulation for DiltiazemHCl tablets 
Ingredient  Batches 
Dtz1 Dtz2 Dtz3 Dtz4 Dtz5 Dtz6 Dtz7 Dtz8 Dtz9 
DiltiazemHCl 120 120 120 120 120 120 120 120 120 
HPMC K4M 75 - - - - - - 20 - 
HPMC K100M - 75 - - 55 35 100 80 80 
Ethyl cellulose - - 75 - 40 40 - - - 
Xanthan gum - - - 75 - - - - - 
Carbopol-934 - - - - - - - - 20 
NaHCO3 50 50 50 50 50 50 50 50 50 
MCC 100 100 100 100 100 100 100 100 100 
Lactose q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Mg Stearate 5 5 5 5 5 5 5 5 5 
Talc 10 10 10 10 10 10 10 10 10 
Total wt. 500 500 500 500 500 500 500 500 500 
* All the ingredients are in mg. 
Optimization of tablet formulation using 3
2
 full 
factorial designs: It is desirable to develop an acceptable 
pharmaceutical formulation in shortest possible time using 
minimum number of man-hours and raw materials. 
Traditionally pharmaceutical formulations are developed 
by changing one variable at a time approach. The method 
is time consuming in nature and requires a lot of 
imaginative efforts. Moreover, it may be difficult to 
develop an ideal formulation using this classical technique 
since the joint effects of independent variables are not 
considered. It is therefore very essential to understand the 
complexity of pharmaceutical formulations by using 
established statistical tools such as factorial design. In 
addition to the art of formulation, the technique of factorial 
design is an effective method of indicating the relative 
significance of a number of variables and their 
interactions.  
The number of experiments required for these 
studies is dependent on the number of independent 
variables selected. The response (Yi) is measured for each 
trial.  
       (1) 
Where Y is the dependent variable, b0 is the 
arithmetic mean response of the nine runs and bi is the 
estimated coefficient for the factor Xi. The main effects 
(X1 and X2) represent the average result of changing one 
factor at a time from its low to high value. The interaction 
terms (X1X2) show how the response changes when two 
factors are simultaneously changed. 
A 32randomized full factorial design was utilized 
in the present study. In this design two factors were 
evaluated, each at three levels, and experimental trials 
were carried out at all nine possible combinations. The 
design layout and coded value of independent factor is 
shown in Table 2 and Table 3 respectively. The factors 
were selected based on preliminary study. The Content of 
HPMCK100M (X
1
) and Content of Carbopol-934 (X
2
) 
were selected as independent variables.  
The selected dependent variables are given below:  
Y1 = Cumulative percentage release (CPR) at 1hr (Q1) 
Y2 = Cumulative percentage release (CPR) at 16hr (Q16) 
Y3 = Floating lag time study in seconds (FLT) 
The formulations of the factorial batches (Dtz9 to Dtz17) 
are shown in Table 4. 
Table 2: Full factorial design Layout 
Batch code X1 X2 
Dtz9 -1 -1 
Dtz10 -1 0 
Dtz11 -1 1 
Dtz12 0 -1 
Dtz13 0 0 
Dtz14 0 1 
Dtz15 1 -1 
Dtz16 1 0 
Dtz17 1 1 
 
Table 3: Coded values for content of HPMC K100M & 
content of carbopol-934 
Coded 
value 
Content of 
 HPMCK100M (mg) 
X1 
Content of  
carbopol-934 (mg) 
X2 
-1 80 20 
0 100 30 
1 120 40 
 
On the basis of the preliminary trials in the 
present study a 32 full factorial design was employed to 
study the effect of independent variables, i.e. content of 
HPMC K100M(X1) and content of carbopol(X2) on 
dependent variables like %drug release at 1 hr.( Q1), %drug 
release at 16 hr.(Q16),& floating lag time.The results 
clearly indicate that all the dependent variables are 
strongly dependent on the selected independent variables 
as they show a wide variation among the nine batches 
(Dtz9 to Dtz17).The fitted equations (full models) relating 
the responses (i.e. Q1, Q16& FLT) to the transformed factor 
were shown in Table 4.The polynomial equation can be 
used to draw conclusions after considering the magnitude 
of coefficient and the mathematical sign it carries, i.e. 
positive or negative.The values of the coefficient are 
shown in Table 5. and the polynomial equations can be 
obtained as follows by using the values of coefficient.
2
222
2
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Table 4: Effect of Independent variable on dependent variable by 3
2
 full factorial design for DiltiazemHCl 
Formulation code Independent variable Dependent variables 
X1 X2 Q1 Q16 FLT(sec.) 
Dtz9 -1 -1 16.99 87.98 157 
Dtz10 -1 0 15.30 87.92 168 
Dtz11 -1 +1 14.45 85.19 181 
Dtz12 0 -1 16.81 83.68 169 
Dtz13 0 0 15.97 80.78 177 
Dtz14 0 +1 13.44 79.54 180 
Dtz15 +1 -1 16.80 74.51 184 
Dtz16 +1 0 12.20 74.96 195 
Dtz17 +1 +1 12.11 73.25 207 
 
Table 5: Summary of regression analysis 
 
Q1 = 15 – 0.9383X 1 – 1.7666X 2 – 0.5375X1X2 -0.765X1
2 + 0.61X2
2(2) 
Q16 = 81.68 – 6.395X 1 – 1.365X 2 + 0.3825X1X2 - 0.69831
2 - 0.5283X2
2(3) 
FLT = 175.55+ 13.33X 1 + 9.66X 2 – 0.25X1X2 + 6.66X1
2 + 0.33X2
2(4) 
 
Table 6: Formulation using 3
2
 full factorial designs 
 
Ingredients 
Batches 
Dtz9 Dtz10 Dtz11 Dtz12 Dtz13 Dtz14 Dtz15 Dtz16 Dtz17 
DitiazemHCl 120 120 120 120 120 120 120 120 120 
HPMCK10M 80 80 80 100 100 100 120 120 120 
Carbopol-934 20 30 40 20 30 40 20 30 40 
NaHCO3 50 50 50 50 50 50 50 50 50 
MCC 100 100 100 100 100 100 100 100 100 
Lactose q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Mg. stearate 5 5 5 5 5 5 5 5 5 
Talc 10 10 10 10 10 10 10 10 10 
Total weight 500 500 500 500 500 500 500 500 500 
* All the ingredients are in mg. 
EVALUATION OF BLEND: 
a) Bulk density: Weight accurately the powder drug, 
which was previously passed through 20# sieve and 
transferred in 100 ml graduated cylinder. The powder was 
carefully level without compacting, and read the unsettled 
apparent volume. The apparent bulk density was calculated 
in gm/ml. 
b) Tapped density: Accurately weighed the powder drug, 
which was previously passed through 20# sieve and 
transferred in 100 ml graduated cylinder. Initial volume 
was observed. The cylinder was tapped up to constant 
volume. 
 
c) Compressibility index: The compressibility of the 
powder was determined by the Carr’s compressibility 
index using the following formula.  
     (5) 
Where, TD-tapped density and LD-loose bulk density 
d) Hausner’s ratio: The Hausner’s ratio is a number that 
is correlated to the flowability of a powder material. 
                (6) 
5) Angle of repose: The angle of repose of powder blend 
was determined by funnel method. Accurately weighed 
powder drug was taken in a funnel. Height of the funnel 
was adjusted in such ways that tip of the funnel just 
  
TD
LDTD 100
index sCarr'


BD
TD
sratioHausner '
Coefficients Q1 Q16 FLT 
b0 15 81.68 175.55 
b1 -0.9383 -6.395 13.33 
b2 -1.7666 -1.365 9.66 
b12 -0.5375 0.3825 -0.25 
b11 -0.765 -0.6983 6.66 
b22 0.61 -0.5283 -0.33 
R
2
 0.8925 0.9871 0.9679 
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touches the apex of the powder drug. The powder mix was 
allowed to flow through the funnel freely onto the surface. 
The diameter of the powder cone was measured and angle 
of repose was calculated using the following equation; 
              (7) 
Where, h and r are the height and radius of the powder 
cone.
 
Table No. 7: Physical properties of powder blend containing DiltiazemHCl 
Formulation code Bulk density 
(gm/ml) 
Tapped density 
(gm/ml) 
Angle of 
Repose (θ) 
Hausner’s ratio Percentage 
compressibility 
Dtz9 0.355±0.02 0.390±0.04 34.9±0.02 1.09±0.03 10.25±0.02 
Dtz10 0.327±0.03 0.360±0.03 29.23±0.02 1.10±0.02 9.1±0.03 
Dtz11 0.331±0.04 0.365±0.02 28.36±0.01 1.10±0.03 9.31±0.03 
Dtz12 0.194±0.03 0.218±0.04 34.23±0.02 1.12±0.03 11±0.02 
Dtz13 0.296±0.03 0.323±0.06 32.12±0.03 1.09±0.04 8.3±0.03 
Dtz14 0.250±0.02 0.269±0.02 31.89±0.01 1.07±0.02 7.06±0.04 
Dtz15 0.260±0.04 0.290±0.03 32.49±0.03 1.11±0.04 10.34±0.04 
Dtz16 0.246±0.04 0.265±0.02 31.87±0.02 1.07±0.03 7.31±0.03 
Dtz17 0.276±0.03 0.300±0.04 34.12±0.04 1.08±0.02 8±0.02 
 
EVALUATION OF FORMULATED TABLET 
1. Weight variation
 
20 tablets were selected randomly from the lot and 
weighed individually to check for weight variation. Weight 
variation specification as per I.P.  
Table 8: Weight Variation Specification as per IP 
Average Weight of Tablet % Deviation 
80 mg or less 10 
More than 80 mg but less   
than 250 mg 
7.5 
250 mg or more 5 
 
2. Hardness 
Hardness or tablet crushing strength (fc) (the force required 
to break a tablet in a diametric compression) was measured 
using Monsanto tablet hardness tester. It is expressed in 
kg/cm2.   
3. Friability (F) 
Friability of the tablet determined using Roche friabiltor. 
This device subjects the tablet to the combined effect of 
abrasion and shock in a plastic chamber revolving at 
25rpm and dropping a tablet at l height of 6 inches in each 
revolution. Preweighted sample of tablets was placed in 
the friabilator and were subjected to the 100 revolutions. 
Tablets were de-dusted using a soft muslin cloth and 
reweighed. The friability (F) is given by the formula.  
 
𝑭 =
𝑾 𝒊𝒏𝒊𝒕𝒊𝒂𝒍 −𝑾(𝒇𝒊𝒏𝒂𝒍)
𝑾(𝒊𝒏𝒊𝒕𝒊𝒂𝒍)
∗ 𝟏𝟎𝟎         (8)
 
Table 9: Physical parameters of prepared tablet containingDiltiazemHCl 
 
All the tablet formulations showed acceptable physical 
parameters and complied with the in house specifications 
for weight variation, hardness and friability. Results are 
shown in Table 9.  Hardness above 3 to 5 kg/cm2 is 
sufficient to prevent breaking of tablets in handling as well 
as during packaging. Friability below 1 % prevents loss of 
material during handling. Weight variation is also 
r
h
tan
Bathes Weight variation (mg) Hardness (kg/cm
2
) %Friability  Drug content 
Dtz9 497 ± 2.78 5.7 ± 0.18 0.77±0.08 100.52±1.24 
Dtz10 500 ± 2.95 5.6 ± 0.39 0.85±0.07 99.32±1.86 
Dtz11 496 ± 2.58 5.8 ± 0.47 0.67±0.04 99.01±1.40 
Dtz12 503 ±2.45 5.6 ± 0.35 0.87±0.03 101.09±1.96 
Dtz13 496 ± 2.37 5.8 ± 0.24 0.74±0.10 99.74±1.34 
Dtz14 503 ± 2.75 5.9 ± 0.14 0.86±0.09 100.57±1.21 
Dtz15 500 ± 2.78 5.7 ± 0.48 0.79±0.05 100.04±1.15 
Dtz16 496 ± 2.86 6.0 ± 0.34 0.95±0.03 98.75±2.32 
Dtz17 502 ± 2.77 6.1 ± 0.27 0.74±0.07 97.33±3.83 
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important consideration, which is ultimately responsible 
for content uniformity.  
In vitro buoyancy studies:In vitro buoyancy studies of all 
factorial design batches were carried out as per the 
procedure given before. All the different formulation has 
floating lag time less than 4 minutes. The pictorial results 
of in vitro buoyancy study of the best batch are shown in 
Figure 1. This clearly depicts the floating lag time, stable 
and persistent buoyancy.All the preliminary trial batches 
were containing different concentration of polymer blend 
in order to optimize content of polymer blend for desirable 
floating time and floating lag time. 
 
Table 10: Floating lag time and floating time of formulation: 
 
Table 10. shows floating lag time and Floating time of 
different formulation. Batch Dtz9, containing 16% of 
HPMCK100M and 4% of Carbopol shows good floating 
time that is more than 24 hrs and floating lag time is 157 
sec. Therefore these combinations of polymers were 
optimized for further study. Other batches Dtz2, Dtz7 and 
Dtz8 also shows good floating time, which is more, then 
24 hrs and also good floating lag time, which is less than 3 
minutes. 32 factorial design (Dtz9-Dtz17) formulation 
showing good floating time and fast floating lag time. 
Swelling index study 
Tablets composed of polymeric matrices build a gel layer 
around the tablet core when they come in contact with 
water. This gel layer governs the drug release. Kinetics of 
swelling is important because the gel barrier is formed 
with water penetration.  
Table 11: Swelling index study of best batch Dtz7 
Time (hrs) % Swelling index 
3  75.34 
6  139.57 
12  182.79 
15  189.34 
18  197.68 
24  203.77 
 
Swelling is also vital factor to ensure floating. To obtain 
floating, the balance between swelling and water 
acceptance must be restored. The swelling index of the 
best batch (Dtz15) at different time intervals was mention 
in Table 11, which may be because of high viscosity and 
high water retention property of HPMC polymer.
 
Figure 1: In vitro buoyancy studies 
(A) Initially                                  (B) After 184 sec.                           (C) After 24hrs 
 
 
Figure 2: Swelling index of best batch Dtz15 
Parameters Dtz9 Dtz10 Dtz11 Dtz12 Dtz13 Dtz14 Dtz15 Dtz16 Dtz17 
Floating lag 
time(sec.) 
157 168 181 169 177 180 184 195 207 
Floating time (hr.) >24 >24 >24 >24 >24 >24 >24 >24 >24 
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Figure 3: Drug release profile of tablet 
Calculation of total dose and theoretical drug release 
profile 
The pharmacokinetics parameters of diltiazemHCl were 
used to calculate a theoretical drug release profile for a 24 
hrs dosage form. The immediate release dose and 
maintenance dose of diltiazemHCl was calculated using 
equation 1 & 2 and was found to be 20.66 mg. and 99.06 
mg. respectively. Hence, the formulation should release 
20.66 mg (17.21%) of drug in initial 1.0 hr. While in the 
remaining 23.0 hrs drug release should be 99.06 mg. So, 
every 1 hrs 4.30 mg (3.58%) of drug release till 23.0 
hrs.Theoritical release profile is shown in Table 6.9.  
Calculation of the loading dose: 
IRD   =  Css × Vd × Body weight  (9) 
F = 20.66mg 21.0 mg 
Calculation of Maintenance Dose (MD) 
Maintenance Dose=  LD Dose (1+ 0.693×t/ t ½)     
                                                                               (10) 
= 99.06 mg 99.0mg 
 Total dose = (21 + 99) mg = 120 mg 
Table 12:  Theoretical release profile of sustained 
release layer 
 
Comparison of dissolution profiles 
The similarity factor (f2) given by SUPAC guidelines for 
modified release dosage form was used as a basis to 
compare dissolution profile. The dissolution profiles are 
considered to be similar when f2 is between 50 and 
100.The dissolution profiles of products were compared 
using f2. This similarity factor is calculated by following 
formula,    
 
 

















 100
1
1log50
5.0
1
2
2
n
t
tt TR
n
f
                      
                                                                                       (11)                                                                       
Where, n is the number of dissolution time and Rtand Tt 
are the reference and test dissolution values at time t. 
In vitro drug release profile of all batches of factorial 
design was compared with theoretical drug release profile. 
The result is shown in Table 13, which indicates that, the 
all the batches except the Dtz9 shows good similarity to 
theoretical release profile. But batch Dtz15 showed the 
highest f2 among all the batches that is 74.76. The 
similarity between the theoretical release profile and the in 
vitro drug release profile of Dtz15 is clearly demonstrated 
in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
Time (hrs) Theoretical release 
profile % 
Range (%) 
0 0 0 
1 17.24 15-20 
4 28.12 20-35 
8 42.50 35-50 
12 56.87 45-65 
16 71.25 65-80 
20 85.62 NLT 80 
24 99.98 - 
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Table 13: Similarity factor amongst the factorial batches 
Formulation 
code 
Dtz9 Dtz10 Dtz11 Dtz12 Dtz13 Dtz14 Dtz15 Dtz16 Dtz17 
Similarity 
factor (f2) 
48.85 50.97 54.07 56.98 62.14 66.35 74.76 72.98 72.48 
 
 
Figure 4: Comparison of theoretical drug release profile and batch Dtz15 
 
Table 14: Comparison of check points between TRP 
and batch Dtz15 
Check 
points 
Theoretical 
value 
Batch 
Dtz15 
Q1 17.24 16.80 
Q16 71.25 74.51 
Q20 85.62 88.18 
f2 50 - 100 74.76 
The results of comparison of various check points between 
theoretical values and batch Dtz15 are shown in table 14. 
The results depicts that the batch Dtz15 shows the good fit 
with the theoretical values. 
RESULT AND DISCUSSION 
In tablet of DiltiazemHCl the loading dose, 
maintenance dose, and theoretical drug release profile was 
calculated based on pharmacokinetics data. Loading dose 
of DiltiazemHCl was released as a burst release from the 
tablet during the initial polymer hydration and the 
remaining drug was released up to 24 hrs as a maintenance 
dose.  
A 32full factorial design was applied to 
systemically optimize in vitro drug release profile. The 
content of HPMC K100M(X1) and content of carbopol 
(X2) were selected as independent variables. The 
cumulative % drug release at1 hr (Q1), cumulative % drug 
release at 16 hr (Q16), floating lag time was selected as 
dependent variables. The result of full factorial design was 
indicated that the X1 (content of HPMC K100M) and X2 
(content of carbopol) both have significant effect on in 
vitro drug release profile. 
As the concentration of carbopol& conc. of 
HPMC K100M increases, the release of drug is retarded 
due to entrapment of drug molecules in the close proximity 
ofcarbopol& HPMC K100M. Use of HPMC K100M 
&carbopol was an advantageous combination for 
formulating gastro retentive tablet. Concentration of 
HPMCK100M was optimized which was 24% (120 mg). 
Concentration of carbopol was optimized which was 4% 
(20 mg).  Floating lag time of all factroialbatchs was less 
than four minutes. From, in vitro dissolution study it was 
observed that batch Dtz15 releases 98.56 % of drug in 24 
hr with floating lag time of 184 seconds. The similarity 
factor f2 was applied between the in vitro drug release 
profile of factorial design batches and theoretical drug 
release profile. No significant difference was observed 
between desired release profile and batches Dtz10 to 
Dtz17. Batch Dtz15 showed highest f2 (f2 = 74.76) among 
all the batches.  Data of kinetic modeling showed that drug 
release mechanism was best explained by higuchi plot and 
value of n (=0.57) indicates the anomalous transport i.e. a 
combined mechanism of pure diffusion and swelling-
controlled drug release. 
Thus it was summarized and concluded that 
gastro retentive tablet of diltiazemHClcan be successfully 
formulated with HPMC K100M and carbopol-934.
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